Loading...
•
Sep 30, 2021
Adaptive Biotechnologies Q3 2021 Earnings Report
Reported strong growth with continued momentum across research, diagnostic and drug discovery.
Key Takeaways
Adaptive Biotechnologies reported a revenue of $39.5 million for Q3 2021, a 50% increase compared to Q3 2020. The company's net loss was $56.0 million, compared to $36.7 million for the same period in 2020.
Revenue of $39.5 million for the third quarter 2021, representing a 50% increase from the third quarter 2020
clonoSEQ clinical sequencing volume in the third quarter 2021 grew 47% versus prior year and 8% over the second quarter of 2021
Launched an enhanced version of the clonoSEQ Assay for CLL patients, which provides IGHV mutation status in the same test where we measure the trackable MRD sequence
Received positive Tech Assessment from MolDX for coverage of T-Detect COVID in certain cases including immunocompromised patients
Forward Guidance
Adaptive Biotechnologies reiterates full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...